Long-term safety of ketamine and esketamine in treatment of depression
Expert Opinion on Drug Safety April 13, 2022 Sina Nikayin, Eva Murphy, John H. Krystal et al. 114 citations
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. Here we review what is known about the long-term safety of both racemic ketamine and esketamine as therapies for psychiatric disorders. AREAS COVERED: In this article, we conducted a safety review...